Efficacy for savolitinib in patients with MET exon 14 alterations is in line with that for other MET tyrosine kinase inhibitors, but safety profile is different
Precision oncology is evolving from advanced to early-stage NSCLC, highlights Prof. Enriqueta Felip in her Heine H. Hansen Award lecture at ELCC 2024
Despite recent progress, lung cancer remains deadly and difficult to treat — and preventable, to a much greater extent with the right actions to improve the quality of the air we breathe
Encouraging EFS and OS results were presented at an ESMO Virtual Plenary for the use of the immune checkpoint inhibitor prior and after surgery
In US, the trend was more frequently seen at very low-volume and nonacademic centers than at high-volume and academic centers
A study identifies some altered inflammatory genes and pathways in non-small cell lung cancer that may be potential targets for overcoming acquired immune resistance
Acquired genomic changes, decreased TILs and HLA class I expression were identified in patients with non-small cell lung cancer progressing on immune checkpoint inhibitors
Certain immunotherapy combinations that are effective in selected solid tumours may not be effective in lung cancer without targetable genetic alterations.
A study reports evidence of antitumour activity by combining a GDF-15 neutralising antibody with PD-1 inhibition in cancers that are refractory/relapsed to immune checkpoint inhibitors
Analysis from MARIPOSA-2 and FLAURA2 trials show a potential change of treatment paradigm in both first- and second-line settings
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.